The COVID-19 pandemic was a stress test for global healthcare infrastructure, and in many ways it exposed just how dependent that infrastructure was on centralised laboratory testing. In the early months of the pandemic, the bottlenecks were painful and sometimes deadly — limited testing capacity, long turnaround times, overwhelmed labs. The pivot to rapid, decentralised point of care testing was arguably one of the most consequential innovations in the entire pandemic response. And the industry that emerged on the other side of COVID is permanently and significantly larger than it was before.

But here's the thing that doesn't get said enough: the pandemic didn't create the POC testing market. It supercharged it. The underlying growth story — driven by ageing populations, rising chronic disease burden, healthcare decentralisation trends, and improving POC technology — was already compelling before COVID. The pandemic just delivered a decade's worth of awareness, regulatory fast-tracking, and commercial investment in about eighteen months. This point of care testing market post-pandemic growth and trends analysis does an excellent job of separating the COVID-driven surge from the structural growth factors, and the picture that emerges is of a market with genuinely durable momentum.

The rapid diagnostics segment — essentially the lab-on-a-strip, lateral flow assay category — received enormous investment and innovation during COVID, and the learnings from that period are now being applied to a whole range of non-COVID infectious diseases. Flu, RSV, strep, monkeypox, HIV, TB, malaria — the list of conditions for which highly sensitive, specific rapid tests are either available or in development is expanding rapidly. Healthcare systems that got comfortable with rapid testing during COVID are now using it as a standard-of-care tool for a much broader range of clinical decisions.

The home testing segment is perhaps the most transformative legacy of the pandemic. Consumer comfort with self-testing — driven by the billions of COVID self-tests distributed globally — has permanently lowered the barrier to at-home diagnostic testing for a wide range of conditions. The point of care and home diagnostics market is now one of the most dynamic consumer health categories, attracting investment from both established diagnostics companies and consumer health startups who see enormous opportunity in putting diagnostic power directly in patients' hands.